Sovran Advisors LLC Acquires New Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Sovran Advisors LLC bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 4th quarter, HoldingsChannel reports. The firm bought 113,457 shares of the biopharmaceutical company’s stock, valued at approximately $2,867,000.

A number of other large investors have also recently made changes to their positions in the stock. KBC Group NV boosted its holdings in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares during the period. AQR Capital Management LLC raised its position in shares of Celldex Therapeutics by 23.7% in the second quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 1,504 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in Celldex Therapeutics by 23.2% during the third quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 2,600 shares during the period. Point72 DIFC Ltd grew its position in Celldex Therapeutics by 101.7% during the third quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock worth $480,000 after buying an additional 7,116 shares in the last quarter. Finally, Creative Planning bought a new position in Celldex Therapeutics in the 3rd quarter worth about $504,000.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $21.53 on Tuesday. Celldex Therapeutics, Inc. has a fifty-two week low of $21.18 and a fifty-two week high of $53.18. The firm has a 50 day moving average price of $25.13 and a 200-day moving average price of $30.40.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on CLDX shares. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, December 19th. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $62.25.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.